Barclays PLC Boosts Holdings in Dianthus Therapeutics, Inc. (NASDAQ:DNTH)

Barclays PLC raised its stake in Dianthus Therapeutics, Inc. (NASDAQ:DNTH) by 390.5% in the 3rd quarter, according to its most recent disclosure with the SEC. The fund owned 41,684 shares of the company’s stock after purchasing an additional 33,185 shares during the quarter. Barclays PLC owned 0.14% of Dianthus Therapeutics worth $1,141,000 at the end of the most recent quarter.

A number of other hedge funds have also recently modified their holdings of the company. Quest Partners LLC boosted its holdings in Dianthus Therapeutics by 112,400.0% in the third quarter. Quest Partners LLC now owns 1,125 shares of the company’s stock valued at $31,000 after acquiring an additional 1,124 shares in the last quarter. Fred Alger Management LLC increased its holdings in shares of Dianthus Therapeutics by 52.5% in the 3rd quarter. Fred Alger Management LLC now owns 9,633 shares of the company’s stock worth $264,000 after purchasing an additional 3,316 shares in the last quarter. SG Americas Securities LLC grew its stake in shares of Dianthus Therapeutics by 104.0% in the third quarter. SG Americas Securities LLC now owns 8,839 shares of the company’s stock worth $242,000 after acquiring an additional 4,506 shares during the period. MetLife Investment Management LLC boosted its stake in shares of Dianthus Therapeutics by 129.1% in the 3rd quarter. MetLife Investment Management LLC now owns 13,939 shares of the company’s stock worth $382,000 after buying an additional 7,854 shares during the last quarter. Finally, American Century Companies Inc. increased its position in shares of Dianthus Therapeutics by 38.6% during the 2nd quarter. American Century Companies Inc. now owns 30,432 shares of the company’s stock valued at $788,000 after purchasing an additional 8,473 shares during the last quarter. Hedge funds and other institutional investors own 47.53% of the company’s stock.

Dianthus Therapeutics Price Performance

Dianthus Therapeutics stock opened at $22.74 on Monday. The firm has a market capitalization of $673.04 million, a P/E ratio of -9.10 and a beta of 1.74. Dianthus Therapeutics, Inc. has a 1-year low of $10.02 and a 1-year high of $33.77. The company’s 50-day moving average is $25.23 and its 200 day moving average is $26.68.

Dianthus Therapeutics (NASDAQ:DNTH) last issued its quarterly earnings results on Thursday, November 7th. The company reported ($0.74) earnings per share for the quarter, missing the consensus estimate of ($0.59) by ($0.15). The business had revenue of $2.17 million during the quarter, compared to analysts’ expectations of $1.07 million. Dianthus Therapeutics had a negative return on equity of 21.68% and a negative net margin of 1,250.32%. Research analysts anticipate that Dianthus Therapeutics, Inc. will post -2.61 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on the company. TD Cowen initiated coverage on Dianthus Therapeutics in a research note on Friday, December 20th. They set a “buy” rating for the company. Raymond James upgraded shares of Dianthus Therapeutics to a “moderate buy” rating in a research report on Thursday, December 12th. Oppenheimer raised their target price on shares of Dianthus Therapeutics from $48.00 to $52.00 and gave the company an “outperform” rating in a research note on Monday, November 11th. Finally, HC Wainwright reissued a “buy” rating and set a $40.00 price objective on shares of Dianthus Therapeutics in a report on Monday, November 11th. Eight analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat, the stock presently has an average rating of “Buy” and a consensus target price of $46.43.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.